Several FDA review officials shared their frustrations with last year's exhilarating but challenging rush to market for highly anticipated biotechnology, biosimilar, vaccine, cell and gene therapies.
A panel of chemistry, manufacturing and controls experts told a rapt audience Jan. 30 at the CASSS WCBP Symposium in...








